An FDA-approved tesamorelin product exists: EGRIFTA, by Theratechnologies, application 022505, a Purple Book biologic. What that approval covers, why an Orange Book search misses it, and why none of it attaches to a research vial.
Every published human study of NAD+ itself, reported precisely: a 180-patient heart-failure trial and an 11-person infusion pilot with a negative finding.
Two published human studies tested NAD+ itself. About 45 randomized trials tested NR or NMN precursors. Why the two evidence bases must never be merged.
No published human interventional trial of MOTS-c exists. The registry record stated precisely, the biomarker-versus-intervention distinction, and the counter-evidence set.
Zero human studies exist for 5-Amino-1MQ or any NNMT inhibitor. How that zero was verified across seven PubMed searches and a registry query, and what it means.
GHK-Cu has exactly two human randomized trials, published in 1992 and 2006. Both were topical, and both were negative on every objective endpoint measured.
Semax has four PubMed records carrying a clinical-trial tag. None were run outside Russia, and the only randomized one reported a negative primary endpoint.
The 2026 WADA Prohibited List names Thymosin-beta4 and its derivatives e.g. TB-500 under section S2.3. Here is the quoted text, the source PDF, and what it covers.
No human trial has ever tested TB-500 itself. The eleven human studies people cite all used thymosin beta-4, the larger parent protein. Here is the full list.
BPC-157 is on the WADA Prohibited List in Section S2, prohibited at all times for tested athletes. What that means, and why the source is no defense.